ArticleThe Lancet regional health. Europe2026
Maternal RSVpreF Immunisation Against Infant RSV Hospitalisation: Nationwide Population-Based Effectiveness and Durability Study.
Article in The Lancet regional health. Europe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Population-level real-world evidence effectiveness on the newly introduced maternal RSVpreF vaccine remains limited. We estimated effectiveness and durability of protection against RSV-associated hospitalisation in infants. Methods: Using the French National Health Data System, we conducted a nationwide study emulating a target trial among infants born between Sept 1 and Dec 31, 2024 in France. Infants born to mothers vaccinated with RSVpreF during pregnancy were matched 1:1 with unimmunised infants on exact date of birth, gestational age, sex, and deprivation status. Follow-up started at birth and continued until Feb 28, 2025. Inverse probability weighting was applied to balance measured covariates. The primary outcome was hospitalisation for RSV-associated lower respiratory tract infection (RSV-LRTI). Secondary outcomes included paediatric intensive care unit admission, oxygen therapy, and ventilatory support. Hazard ratios were estimated using Cox models, and vaccine effectiveness calculated as (1-HR) × 100. Findings: Among 31,356 infants included in the matched cohort (15,678 per group; median follow-up 86 days [IQR 73-101]), 693 RSV-LRTI hospitalisations occurred, including 216 (1·4%) among immunised infants and 477 (3·0%) among unimmunised. Maternal RSVpreF immunisation was associated with a reduced risk of RSV-LRTI hospitalisation (HR 0·50, 95% CI 0·45-0·55), corresponding to an effectiveness of 50% (95% CI 45-55). Protection was highest during days 0-14 after birth (66%, 95% CI 58-73) and declined thereafter to 38% (95% CI 19-52) during days 60-75. Reductions were also observed for severe outcomes, including RSV-LRTI requiring paediatric intensive care unit admission (74 (0·5%) vs 158 (1·0%); effectiveness 51%, 95% CI 43-57), oxygen therapy (59 (0·4%) vs 136 (0·9%); effectiveness 54%, 95% CI 46-60), and ventilatory support (65 (0·4%) vs 137 (0·9%); effectiveness 53%, 95% CI 45-59). Interpretation: Maternal RSVpreF immunisation reduced RSV-associated hospitalisation in infants, with protection strongest early in life and declining thereafter. Funding: No funding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.